In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 49 for your search:
Drug:  alemtuzumab
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2006-006130-17, NCT00646854

3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL 2006-1B / ACT-2, BMBF GFVT 01014715, NCT00725231

4.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CM-2008-01, 08/H0720/15, 74928896, NCT01077908

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: NHLBI-02-H-0250, NCT00047060

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 8713-HIMSUM, NCT00058825

7.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TSRCC-164-2006, NCT00363090

8.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144

10.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL2I, CLL2I, BAYER-GCLLSG-CLL2I, EU-20816, NCT00634881

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CCI #07-00119, CHLA-#07-00119, NCT00730314

12.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MC088C, NCI-2009-00935, 08-008775, NCT00935792

13.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-0132, NCT00943319

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AGMT CLL-6 BendAlem, NCT00951457

15.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LS1084, NCI-2010-02329, 10-003025, NCT01269385

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RHM CAN0638, 2008-007043-14, NCT01422603

17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NHLBI
Protocol IDs: 050206, 05-H-0206, NHLBI-05-H-0206, NCT00217594

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: MF/SS, NCT00157274

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000462406, UCSF-04152, UCSF-00452, UCSF-H411-25738-02, NCT00301834

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: NHLBI
Protocol IDs: 060190, 06-H-0190, NHLBI-06-H-0190, NCT00345345

21.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: LCC-CTRU-CLL207, SPRI-LCC-CTRU-CLL207, ISRCTN23153249, EU-20715, EUDRACT-2006-000053-22, NCT00458523, CLL207

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: 2007.00, NCI-2009-01550, P01HL036444, FHCRC-2007.00, 6301, NCT00553098

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and under
Sponsor: Other
Protocol IDs: BCM-H-10915, H 10915, BCM-SAA-MUD, NCT00598221

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 00003567, NCT00597714

25.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000594797, MAYO-LS0881, LS0881, NCT00669318
1   
New Search